Boundless Bio, Inc.
BOLDBoundless Bio, Inc. in brief
Boundless Bio, Inc. is a listed company in the Biotechnology industry, based in La Jolla, California, USA. Its market value was $59 M on 29 October 2026, which makes it the 20,669th largest listed company in the world and the 3,788th largest in the USA on this site. It employs about 28 people and Zachary Hornby is its chief executive. Its shares trade under the symbol BOLD (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Boundless Bio, Inc.
We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14 to 17% of cancer patients. Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.
ecDNA are large circular units of nuclear DNA that are a primary mechanism of gene amplification and are detected only in cancer cells, not in healthy cells. Despite tremendous advancements in treating cancer broadly, patients with oncogene amplified cancers generally derive little benefit from existing therapies, such as molecular targeted therapies or immunotherapies, and have worse survival rates than patients without oncogene amplification. Using our proprietary Spyglass platform, we identify targets essential for ecDNA functionality in oncogene amplified cancer cells, then design and develop small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets, with the aim to prevent cancer cells from using chromosomal instability (CIN) and ecDNA amplification biology to grow, adapt, and become resistant to existing therapies. Instead of directly targeting the proteins produced by amplified oncogenes, which is the approach of traditional targeted therapies, our ecDTx are intended to be synthetic lethal in tumor cells reliant on ecDNA amplification biology. In the context of drug development, synthetic lethality is a therapeutic approach wherein using a drug to inhibit one target is lethal to cancer cells harboring a specific genetic alteration to a second target, but not lethal to healthy cells that lack the genetic alteration to the second target.
From the company's annual report filed with the US SEC: read the report
Boundless Bio, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 28 March 2024; shares registered for exchange trading on 22 March 2024.
Events of Boundless Bio, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,644 (Aug 2026) · #3,747 (Oct 2026) · #3,791 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.6×
- Free cash flow yield
- -80.0%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -59.0%
- Liabilities / assets
- 37.2%
- Profit per employee
- $-2.1 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-64M | $-58M | — |
| Dec 2024 | — | — | $-73M | $-65M | — |
| Dec 2023 | — | — | $-55M | $-49M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-47M | $1M | $-47M | $-2.60 | — |
| Dec 2024 | $-61M | $3M | $-63M | $-3.85 | — |
| Dec 2023 | $-47M | $1M | $-47M | $-40.65 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Aug 28, 20268-KCurrent reportMaterial agreement
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Jun 23, 20268-KCurrent reportMaterial agreement · Restructuring costs · Unregistered share sale · Change in control · Directors or officers changed · Regulation FD disclosure · Other events
- Jun 17, 20268-KCurrent reportShareholder vote
- May 8, 202610-QQuarterly report · period to Mar 2026
- May 8, 20268-KCurrent reportResults of operations
- Apr 28, 2026DEF 14AProxy statement
- Apr 13, 20268-KCurrent reportAgreement ended · New financial obligation
- Mar 9, 202610-KAnnual report · period to Dec 2025
- Mar 9, 20268-KCurrent reportResults of operations · Directors or officers changed
- Nov 5, 202510-QQuarterly report · period to Sep 2025
Official filings of Boundless Bio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-64 M
- Net income
- $-58 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $157 M
- Total liabilities
- $58 M
- Total equity
- $99 M
As of December-2025
Top 42 institutional investors in Boundless Bio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Tang Capital Management LLC | 2,840,635 | +280,760 (+10.97%) | 12.03% | $7 M | Nov 16, 2026 |
| 2 | ARCH Venture Management, LLC | 2,694,095 | 0 (0.00%) | 11.41% | $7 M | Nov 16, 2026 |
| 3 | FMR LLC | 2,564,355 | -16,700 (-0.65%) | 10.86% | $6 M | Nov 10, 2026 |
| 4 | ADAR1 Capital Management, LLC | 1,893,439 | -74,777 (-3.80%) | 8.02% | $5 M | Nov 16, 2026 |
| 5 | Cormorant Asset Management, LP | 940,000 | -60,000 (-6.00%) | 3.98% | $2 M | Nov 16, 2026 |
| 6 | Vanguard Capital Management LLC | 597,192 | -17,731 (-2.88%) | 2.53% | $1 M | Nov 13, 2026 |
| 7 | Wellington Management Group LLP | 556,233 | 0 (0.00%) | 2.36% | $1 M | Nov 16, 2026 |
| 8 | Renaissance Technologies LLC | 493,500 | +21,930 (+4.65%) | 2.09% | $1 M | Nov 12, 2026 |
| 9 | Two Sigma Investments, LP | 375,399 | New | 1.59% | $1 M | Nov 16, 2026 |
| 10 | Acadian Asset Management LLC | 347,173 | +200,416 (+136.56%) | 1.47% | $1 M | Nov 9, 2026 |
| 11 | Alyeska Investment Group, L.P. | 300,000 | 0 (0.00%) | 1.27% | $1 M | Nov 16, 2026 |
| 12 | China Universal Asset Management Co., Ltd. | 233,300 | +216,400 (+1280.47%) | 0.99% | $1 M | Oct 28, 2026 |
| 13 | Superstring Capital Management LP | 206,242 | +150,886 (+272.57%) | 0.87% | $1 M | Nov 16, 2026 |
| 14 | RBF Capital, LLC | 200,000 | 0 (0.00%) | 0.85% | $1 M | Nov 13, 2026 |
| 15 | Citadel Advisors LLC | 158,263 | +13,214 (+9.11%) | 0.67% | $0 M | Nov 16, 2026 |
| 16 | Ensign Peak Advisors, Inc | 133,594 | -26,241 (-16.42%) | 0.57% | $0 M | Nov 12, 2026 |
| 17 | Geode Capital Management, LLC | 129,672 | +12,936 (+11.08%) | 0.55% | $0 M | Nov 6, 2026 |
| 18 | Vanguard Fiduciary Trust Co | 108,415 | +43,279 (+66.44%) | 0.46% | $0 M | Nov 13, 2026 |
| 19 | State Street Corp | 100,662 | +84,700 (+530.64%) | 0.43% | $0 M | Nov 12, 2026 |
| 20 | BlackRock, Inc. | 85,786 | -2,709 (-3.06%) | 0.36% | $0 M | Nov 13, 2026 |
| 21 | Bridgeway Capital Management, LLC | 77,500 | -50,500 (-39.45%) | 0.33% | $0 M | Nov 16, 2026 |
| 22 | XTX Topco Ltd | 70,912 | +37,551 (+112.56%) | 0.30% | $0 M | Nov 16, 2026 |
| 23 | Rangeley Capital, LLC | 68,000 | -6,000 (-8.11%) | 0.29% | $0 M | Nov 16, 2026 |
| 24 | Marshall Wace, LLP | 54,031 | New | 0.23% | $0 M | Nov 13, 2026 |
| 25 | Stonepine Capital Management, LLC | 52,547 | -102,048 (-66.01%) | 0.22% | $0 M | Nov 13, 2026 |
All 42 institutional investors: 26 to 42, with who bought and sold →
Mutual funds holding Boundless Bio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC | 900,270 | $1 M | 3.8% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 445,181 | $1 M | 1.9% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 152,011 | $0 M | 0.64% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC | 226,498 | $0 M | 0.96% | <0.01% | −1.3% | May 31, 2026 |
| 🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC | 202,816 | $0 M | 0.86% | <0.01% | −13% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 58,851 | $0 M | 0.25% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 50,500 | $0 M | 0.21% | 0.09% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 82,655 | $0 M | 0.35% | <0.01% | +22% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 17,731 | $0 M | 0.08% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 15,411 | $0 M | 0.07% | <0.01% | +40% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 8,946 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 4,089 | $0 M | 0.02% | <0.01% | +38% | Jun 30, 2026 |
As of Jun 30, 2026
Insider trading at Boundless Bio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kevin Tang10% owner | Buyindirect | +12,417 | $2.400 | $30 K | 3.05 M | Form 4 |
| filed | Kevin Tang10% owner | Buyindirect | +1,395 | $2.400 | $3 K | 3.04 M | Form 4 |
| filed | Kevin Tang10% owner | Buyindirect | +249 | $2.400 | $598 | 3.04 M | Form 4 |
| filed | Kevin Tang10% owner | Buyindirect | +1,700 | $2.400 | $4 K | 3.04 M | Form 4 |
| filed | Kevin Tang10% owner | Buyindirect | +8,390 | $2.400 | $20 K | 3.03 M | Form 4 |
| filed | Kevin Tang10% owner | Buyindirect | +517 | $2.400 | $1 K | 3.03 M | Form 4 |
| filed | Kevin Tang10% owner | Buyindirect | +2,255 | $2.400 | $5 K | 3.02 M | Form 4 |
| filed | Kevin Tang10% owner | Buyindirect | +10,707 | $2.400 | $26 K | 3.02 M | Form 4 |
Markets and events: Boundless Bio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split
Trading halts
- 2026-06-23 11:25 UTC, code T3, resumed 11:50 UTC
- 2026-01-20 11:55 UTC, code T3, resumed 12:30 UTC
Fails to deliver
- : 6,677 shares at $2.50
- : 149 shares at $2.44
- : 5,254 shares at $2.64
- : 980 shares at $2.62
- : 1,290 shares at $2.83
Boundless Bio, Inc. scorecard#
Passes 2 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 4
Growth0 of 1
Profitability0 of 2
Financial health1 of 2
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Boundless Bio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | 45 | 55 | 43 | |
| General and administrative | 19 | 18 | 12 | |
| Operating expenses | 64 | 73 | 55 | |
| Operating income | −64 | −73 | −55 | |
| Interest and finance income | 5.4 | 7.9 | 5.3 | |
| Other non-operating income (expense) | 5.4 | 7.9 | 5.4 | |
| Income tax | 0 | 0 | — | |
| Net income including minority interests | −58 | −65 | −49 | |
| Net income attributable to shareholders | −58 | −65 | −49 | |
| Earnings per share, basic | -2.60 | -3.85 | -40.65 | |
| Earnings per share, diluted | -2.60 | -3.85 | -40.65 | |
| Shares, weighted average (basic) | 22 | 17 | 1.2 | |
| Shares, weighted average (diluted) | 22 | 17 | 1.2 | |
| Balance sheet | ||||
| Cash and cash equivalents | 18 | 27 | 24 | |
| Short-term investments | 90 | 126 | 97 | |
| Other current assets | 2.0 | 2.3 | 3.5 | |
| Current assets | 110 | 154 | 124 | |
| Property, plant and equipment | 3.2 | 4.3 | 2.6 | |
| Right-of-use (leased) assets | 44 | 47 | 2.0 | |
| Total assets | 157 | 206 | 130 | |
| Accounts payable | 1.5 | 1.3 | 2.2 | |
| Current liabilities | 13 | 8.1 | 9.4 | |
| Lease liabilities (non-current) | 46 | 48 | — | |
| Total liabilities | 58 | 56 | 9.4 | |
| Retained earnings | −260 | −201 | −136 | |
| Shareholders' equity | 99 | 151 | −127 | |
| Total equity | 99 | 151 | −127 | |
| Total liabilities and equity | 157 | 206 | 130 | |
| Shares outstanding | 22 | 22r | 0.0r | |
| Cash-flow statement | ||||
| Depreciation and amortization | 1.3 | 1.1 | 1.0 | |
| Share-based compensation | 6.1 | 7.5 | 3.3 | |
| Cash from operating activities | −47 | −61 | −47 | |
| Capital expenditure | −0.5 | −2.5 | −0.6 | |
| Cash from investing activities | 38 | −26 | −38 | |
| Cash from financing activities | 0.1 | 90 | 98 | |
| Change in cash | −8.7 | 2.9 | 13 | |
| Report | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2026
Events at Boundless Bio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 2 · Change in control 1 · Directors and officers 5 · Material agreement 3 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Material agreement | 8-K | |
| RestructuringChange in controlDirectors and officersMaterial agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Agreement endedNew debt | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Restructuring | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K |
As of Aug 28, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — | |
| 2025 | · | · | · | · | · | · | · | · | · | · | · | · | — |
How Boundless Bio, Inc. compares in Biotechnology
- Market cap$59 M · higher than 28% of 726
- Price / book0.6× · lower than 89% of 534
- FCF yield-80.0% · higher than 13% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Boundless Bio, Inc.🇺🇸 | $59 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Oneness Biotech Co., Ltd.$520 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
How current the figures are
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 8, 2026
- Profile updated:
- Nov 21, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Boundless Bio, Inc.? Verify and update this profile — free
Show Boundless Bio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.